Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001010297 | SCV001170471 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-01-19 | criteria provided, single submitter | clinical testing | The p.N40K variant (also known as c.120C>G), located in coding exon 1 of the FH gene, results from a C to G substitution at nucleotide position 120. The asparagine at codon 40 is replaced by lysine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV002549316 | SCV001200476 | likely benign | not provided | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001037079 | SCV001458388 | uncertain significance | Fumarase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |